Navigation Links
HCA Reports First Quarter 2009 Results
Date:4/27/2009

) on sales of facilities and impairment of long-lived assets and adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe that it is useful to investors to provide disclosures of our results of operations on the same basis as that used by management. Management relies upon net income attributable to HCA Inc., excluding losses (gains) on sales of facilities and impairment of long-lived assets and adjusted EBITDA as the primary measures to review and assess operating performance of its hospital facilities and their management teams. Management and investors review both the overall performance (including; net income attributable to HCA Inc., excluding losses (gains) on sales of facilities and impairment of long-lived assets and GAAP net income attributable to HCA Inc.) and operating performance (adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the adjusted EBITDA margin (adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and impairments of long-lived assets will occur in future periods, but the amounts recognized can vary significantly from quarter to quarter, do not directly relate to the ongoing operations of our health care facilities and complicate quarterly comparisons of our results of operations and operations comparisons with other health care companies. Net income attributable to HCA Inc., excluding losses (gains) on
'/>"/>
SOURCE HCA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
2. Neovasc Inc. Reports Year 2008 Financial Results
3. NBTY Reports Second Quarter Results
4. Statement from USPA Exec. Dir. on News Reports of Florida Pharmacy Admission of Error in the Medicine Dispensed to the Horses Who Died on Sunday
5. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
6. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
7. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
8. Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results
9. CuraGen Reports First Quarter 2009 Financial Results
10. NuVasive Reports First Quarter 2009 Financial Results
11. Torchmark Corporation Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... 23, 2014Men whose testosterone falls below normal levels are ... overweight and have heart disease and type 2 diabetes. ... men for further testing and possible treatment is described ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ... Journal of Men,s Health website at http://www.liebertpub.com/jmh ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... ACM Technology To Make Medical Pharmacy Claims Processing ... announced today the signing of,a new three-year contract ... it,easier for providers to submit claims for complex ... health plan. ACM,s proprietary,e-Precision claims(SM) technology will streamline ...
... 15 Althea Technologies, Inc., a leading,provider ... and manufacturing, announced today that E.J. Brandreth ... Quality and Regulatory. In this,role, Mr. Brandreth ... and,compliance programs, while overseeing the regulatory support ...
... recently held its 2008 Live Group Buy for Magnetic Resonance Imaging ... Hitachi Medical Systems America Inc. , ... Dallas, TX ... Group Buy for Magnetic Resonance Imaging (MRI), and Broadlane’s clients awarded ...
... Financial District Office Workers, Celebrities, Sports Personalities, and Corporate CEO's, are ... , ... San Francisco (PRWEB) July 15, 2008 -- ... United States has chosen Peacock Construction to bring his ...
... E-Prescribing Solution Can Help Organizations Achieve Benefits of H.R. 6331 ... ... Netsmart Technologies, Inc., a leading provider of enterprise-wide software and services ... special Web seminar to help behavioral health organizations understand e-prescribing ...
... ANGELES (STRICTLY EMBARGOED UNTIL JULY 15, 2008 AT 12:01 A.M. ... cell vaccine designed to fight malignant brain tumors called glioblastoma ... a patient,s immune response and clinical outcome, according to an ... Cancer Research . , While other studies have suggested a ...
Cached Medicine News:Health News:Blue Shield of California and ACM Sign New 3-Year Agreement 2Health News:Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 3Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 4Health News:Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 3Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 2Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 3
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa...
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... Since its U.S. approval in 1992, ABIOMED's ... widely used advanced cardiac assist system in the ... only device approved by the U.S. Food and ... heart failure. ABIOMED continues to make advances ...
... The Arrow LionHeart Left Ventricular Assist ... is designed to be used as a ... end-stage (Class IV) congestive heart failure, for ... The Arrow LionHeart LVAS is not intended ...
Medicine Products: